theglobeandmail.comOCT 41 min read$TFX

RBC Capital Reaffirms Their Buy Rating on Teleflex (TFX)

RBC Capital reaffirmed a Buy rating on Teleflex (TFX) with a $155 target. Shares closed at $126.11. Analyst consensus is Moderate Buy with $157.67 avg target. Q2 revenue was $570.33M, down from $780.89M YoY.

Original reporting

theglobeandmail.com

Published Oct 4, 2026, 2:00 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 4, 2026, 5:51 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

RBC Capital Reaffirms Their Buy Rating on Teleflex (TFX) — source image — Source · theglobeandmail.com

Decision brief

The 30-second read

$TFXBullishLow

Why it matters

The reaffirmed Buy and higher target suggest a modest positive bias but the underlying earnings weakness tempers enthusiasm.

Market read

Analyst upgrade offers a small trading edge for TFX, but limited broader market effect.

What to watch

Teleflex's declining revenue and profit margins could limit upside despite the higher target.

Relevance 4/10Novelty 3/10Timing: today

Background

Teleflex reported Q2 results with revenue down year‑over‑year and a net profit decline, prompting analyst coverage.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TFXBullishMedium confidence

Context

RBC Capital reaffirmed a Buy rating on Teleflex and raised the price target to $155, providing a fresh analyst upgrade.

Expected impact

likely modest upside as investors price in the higher target

Evidence & confidence

The upgrade is a new recommendation but lacks a catalyst beyond the rating change, so impact is limited.

Market effects

Sector

May slightly lift sentiment in the broader medical device sector.

Regional

Minimal impact on US markets.

Global

Limited to investors tracking healthcare equities.

Counterpoint

What could challenge this read

The rating upgrade may be premature given recent revenue decline.

Key entities

Company
Teleflex
Medical device manufacturer (ticker TFX).
Analyst Firm
RBC Capital
Provided the rating upgrade.

Read at source ← All news

OCT 12

$TFXLow

Teleflex completes enrollment in coronary scaffold study

Teleflex (NYSE:TFX) completed enrollment in its BIOMAG-LL study, evaluating longer Freesolve Resorbable Magnesium Scaffolds for coronary lesions. The trial enrolled 102 patients across Europe, with primary endpoint being Target Lesion Failure rate at 12 months. The study is part of expanding the Freesolve RMS portfolio, according to the company.

investing.com1 min

OCT 12

$TFXLowAI 8/10

102 patients joined a study of longer artery supports designed to be absorbed

Teleflex Inc. completed enrollment of 102 patients in the BIOMAG™-LL Clinical Study across 14 European centers to evaluate 35 mm and 40 mm Freesolve™ Resorbable Magnesium Scaffolds for long coronary lesions. The study aims to assess safety and effectiveness, with primary endpoint Target Lesion Failure (TLF) rate at 12 months. The data could expand treatment options for diffuse coronary artery disease, supporting the broader use of resorbable scaffold technology.

stocktitan.net2 min

OCT 1

$TFXMed

Teleflex Incorporated (TFX) Stock Forecasts

Argus raised its target price for Teleflex Incorporated (TFX) to $133.00. The company, based in Wayne, Pennsylvania, manufactures hospital supplies and medical devices. No other details were provided.

finance.yahoo.com1 min

SEP 29

$PACBMed

Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex

PacBio (PACB) rose 5.8% after a $27.1M contract with the U.S. Department of Veterans Affairs. Nvidia (NVDA) gained 2.7% following a $150B share buyback authorization. Palo Alto Networks (PANW) increased 5.1% after BTIG raised its price target to $425. Teleflex (TFX) climbed 4.5% following a BofA Securities upgrade.

markets.financialcontent.com2 min

SEP 28

$TFXHigh

Why Teleflex (TFX) Stock Is Trading Up Today

Teleflex (TFX) stock rose 4.5% after BofA Securities upgraded it to Buy and raised its price target to $158 from $145. The shares closed at $127.39, up 4.4%. The company's shares have been volatile, with significant moves over the past year, including a 15.5% drop after a weak earnings report. TFX is up 4.1% year-to-date but remains 10.3% below its 52-week high.

financialcontent.com2 min